Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Anders Olsson1

  • 1Linkopings universitet Institutionen for medicin och halsa - Linkoping, Sweden Inst för Medicinska vetenskaper, Linköping - Bromma, Sweden.

Lakartidningen
|January 30, 2019
PubMed
Summary

The ODYSSEY trial showed that alirocumab significantly reduced cardiovascular events and total death by 15% in patients with recent acute coronary syndrome. This PCSK9 inhibitor therapy was found to be safe and well-tolerated over 2.8 years.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Measuring thyroid-stimulating hormone receptor antibodies using the IMMULITE<sup>®</sup> 2000 TSI assay is better than using the BRAHMS TRAK assay in an unselected clinical population, but both perform worse than expected: a real-world retrospective observational study.

Thyroid research·2026
Same author

Performance of enzymatic creatinine methods in the pediatric concentration range.

Scandinavian journal of clinical and laboratory investigation·2025
Same author

Empowering Regional Conservation: Genetic Diversity Assessments as a Tool for Eelgrass Management.

Molecular ecology·2025
Same author

Calculation of continuous reference intervals for biological parameters exhibiting strong age-dependent level changes: Its application to glycosaminoglycans and sialic acid in urine.

JIMD reports·2024
Same author

A bispecific CD40 agonistic antibody allowing for antibody-peptide conjugate formation to enable cancer-specific peptide delivery, resulting in improved T proliferation and anti-tumor immunity in mice.

Nature communications·2024
Same author

Caprin-1 binding to the critical stress granule protein G3BP1 is influenced by pH.

Open biology·2023

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology

Context:

  • Patients with recent acute coronary syndrome (ACS) often require intensive lipid-lowering therapy.
  • High-dose statin therapy may not be sufficient for all ACS patients to reach lipid goals.
  • The ODYSSEY outcome study evaluated an add-on therapy to statins.

Purpose:

  • To investigate the efficacy and safety of alirocumab in reducing cardiovascular events in high-risk patients.
  • To assess the impact of alirocumab on major adverse cardiovascular events (MACE) and all-cause mortality.

Summary:

  • The study involved subjects with recent ACS on high-dose statins, treated with 75-150 mg alirocumab subcutaneously every 2 weeks for 2.8 years versus placebo.
  • Alirocumab reduced the risk of the primary composite endpoint (coronary death, myocardial infarction, angina, ischemic stroke) by 15%.
  • A 15% reduction in total mortality was also observed; the drug was safe and tolerable.

Impact:

  • Alirocumab demonstrates significant cardiovascular risk reduction in ACS patients inadequately managed by statins alone.
  • The findings support alirocumab as a valuable therapeutic option for secondary prevention in high-risk cardiovascular populations.
  • This study contributes to understanding the long-term benefits of PCSK9 inhibition in managing atherosclerotic cardiovascular disease.

Related Experiment Videos